La TEP-TDM dans la maladie de Hodgkin : expérience clermontoise |
| |
| Institution: | 1. Division of Stem Cell and Molecular Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan;2. Department of Hematology, Kobe City Hospital Organization, Kobe City Medical Centre General Hospital, Kobe, Japan;3. Department of Environmental Medicine and Population Science, Graduate School of Medicine, Osaka University, Suita, Japan;4. Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan;5. Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan;6. Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan;7. Division of Hematology, Jichi Medical University, Shimotsuke, Japan;8. Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan;9. Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan;10. Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan;11. Department of Hematology, University of Tsukuba Hospital, Tsukuba, Japan;12. Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan;13. Department of Hematology, Shinshu University School of Medicine, Matsumoto, Japan;14. Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan;15. Preparation Department, Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan;16. Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan;17. Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan;18. Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan;19. Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan;20. Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan |
| |
| Abstract: | The aim of this study was to evaluate the standardized uptake value (SUV) of 18FDG in Hodgkin's disease according to various histopathologic parameters as well as the impact of the examination on stadification and follow-up. A total of 37 patients profited from a pretherapeutic PET-CT. Standardized uptake value was calculated a posteriori. This one is higher in mixed cellularity Hodgkin's disease compared to nodular sclerosing Hodgkin's disease. In addition, the examination involved a change of stage in 35% of the cases compared to the injected CT. The specificity of the PET-CT at the end of the treatment was 96% and its exactitude of 93%, both significantly higher than those found in CT. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
